Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

about

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

Item

http://www.wikidata.org/entity/Q40990450

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical features of lenvatini ...... with advanced thyroid cancer.

@en

type

Item

label

Clinical features of lenvatini ...... with advanced thyroid cancer.

@en

prefLabel

Clinical features of lenvatini ...... with advanced thyroid cancer.

@en

P1476

Clinical features of lenvatini ...... with advanced thyroid cancer.

@en

P2093

Aiko Sueta

http://www.w3.org/2001/XMLSchema#string

Hirotaka Iwase

http://www.w3.org/2001/XMLSchema#string

Koichi Suyama

http://www.w3.org/2001/XMLSchema#string

Mutsuko Yamamoto-Ibusuki

http://www.w3.org/2001/XMLSchema#string

Saori Fujiwara

http://www.w3.org/2001/XMLSchema#string

Touko Inao

http://www.w3.org/2001/XMLSchema#string

Yutaka Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.

Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis

Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials.

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

P304

24-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1265

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Takashi Takeshita

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28685069

http://www.w3.org/2001/XMLSchema#string

P932

5492816

http://www.w3.org/2001/XMLSchema#string